Donor Transmission of Melanoma Following Renal Transplant

Chen, Kathryn T.; Olszanski, Anthony J.; Farma, Jeffrey M.

doi:10.1155/2012/764019

Cited by 5 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite careful donor selection, cancer transmission to the recipient is inevitable [1]. Malignant melanoma is considered to be an immunogenic tumor, which changes its malignant potential with the exposure to immunosuppression [1,2]. Melanoma could remain dormant chronically in the immunocompetent population.…”

Section: Discussionmentioning

confidence: 99%

“…There is a lack of consensus regarding the management for donor-derived melanoma. Early diagnosis, cessation of immunosuppression to allow rejection of the allograft and transplanted cancer cells, transplant nephrectomy are the usual standards in patients with kidney transplant [1,2]. Unfortunately, this is not a feasible option for patients with transplanted organs other than kidneys (heart, lung, and pulmonary) due to a lack of viable alternative therapies to the transplanted organs.…”

Section: Discussionmentioning

confidence: 99%

“…Novel therapy like check-point inhibitors (for instance, Ipilimumab) is changing the landscape of treatment of metastatic melanoma in the general population. However, check-point inhibitors have been successfully utilized only twice in donor-derived melanoma [2,3]. We present here, the longest disease-free survival in a patient with donor-derived melanoma with ipilimumab.…”

Section: Introductionmentioning

confidence: 91%

See 2 more Smart Citations

Successful Treatment and Five Years of Disease-free Survival in a Donor Transmitted Metastatic Melanoma with Ipilimumab Therapy

Singh¹,

Pandey²,

Rovin³

et al. 2019

Cureus

View full text Add to dashboard Cite

Approximately 7% of deceased donors have unknown cancer at the time of organ procurement. More than half of these have no apparent contraindication to organ donation. The commonest transmitted malignancy is renal cell cancer (19%), followed by melanoma (17%). Donor transmission of melanoma has been fatal in most cases as it is commonly metastatic at the time of diagnosis. Till date, there have been only a few cases with remission of melanoma following transplant nephrectomy and withdrawal of immunosuppression. To our knowledge, the evidence presented here is only the second case of donor-derived melanoma that was successfully treated with Ipilimumab. Our patient has the longest disease-free survival (five years) reported in the literature to date.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Successful Treatment and Five Years of Disease-free Survival in a Donor Transmitted Metastatic Melanoma with Ipilimumab Therapy

Singh¹,

Pandey²,

Rovin³

et al. 2019

Cureus

View full text Add to dashboard Cite

show abstract

Update in Melanoma in Organ Transplant Patients

Wysong

Soon

2014

Advances in Transplant Dermatology

View full text Add to dashboard Cite

Management of Renal Cell Carcinoma and Other Renal Masses in the Kidney Graft

Warren

Olsburgh

2020

Curr Urol Rep

View full text Add to dashboard Cite

Purpose of Review Renal masses in the kidney graft pose an important clinical dilemma, balancing graft function against the need for cancer control. Recent Findings Donor origin cancers in the renal graft can be classified as 'donor transmitted' or 'donor derived'. The landmark TracerX Renal changed our understanding of renal cell carcinoma oncogenesis, demonstrating that key mutations in childhood lead to clinically apparent tumours in later life. Identified pre-operatively, contemporary evidence suggests that masses excised prior to transplantation result in acceptable oncologic safety and graft function. Identified post-operatively management mirrors that for a mass in a solitary kidney in the non-transplant population, with focus on a nephron-sparing approach. Summary With growing number of kidney transplants each year, ageing donors, and increasing graft survival, masses in the renal graft are likely to become a more prevalent clinical conundrum.

show abstract

Donor Transmission of Melanoma Following Renal Transplant

Cited by 5 publications

References 20 publications

Successful Treatment and Five Years of Disease-free Survival in a Donor Transmitted Metastatic Melanoma with Ipilimumab Therapy

Successful Treatment and Five Years of Disease-free Survival in a Donor Transmitted Metastatic Melanoma with Ipilimumab Therapy

Update in Melanoma in Organ Transplant Patients

Management of Renal Cell Carcinoma and Other Renal Masses in the Kidney Graft

Contact Info

Product

Resources

About